Centers | ||
|
|
|
EU-OPENSCREEN | BLAVATNIK CENTER for Drug Discovery | Chemical Genomics Facility at Purdue Institute for Drug Discovery |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
The BLAVATNIK CENTER for Drug Discovery (BCDD) is a fully integrated center for translational research, based at Tel Aviv University, that comprises medicinal chemistry, biological target identification and computer-assisted drug design units under... Read more |
The Chemical Genomics Facility is a core facility at Purdue Institute for Drug Discovery that provides expertise and resources needed in the early stage of drug discovery. The services include small molecule libraries, access to automated equipment... Read more |
Partnerships |
Events |
Jobs |
Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all Bayer and UCSF Enter into a 10year Research & Development PartnershipBayer and University of California, San Francisco (UCSF) have signed a 10year master research and development agreement. The agreement provides a broad template for collaboration between the two groups around common areas of research interest... View all Janssen Partners with Evotec-Harvard Diabetes Collaboration ProgramJanssen Pharmaceutical a division of Johnson & Johnson has entered into partnership with Harvard University - Evotec's Diabetes program called CureBeta. Janssen will paying $300million in milestone payments per product in addition to $8million in... View all |
No EVENTS for listing |
No Job Posts |
